Meditor Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Meditor Group’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,149	Closed	-$142K	–	4
2015 Q4	$142K	Sell	3,149 -9,629	-75%	-$420K	0.07%	4
2015 Q3	$480K	Buy	+12,778	New	+$587K	0.25%	4

Other funds holding RCKT

DPA

Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Meditor Group's RCKT Position: Q1 2016 in Review

Meditor Group sold out of Rocket Pharmaceuticals (RCKT) in Q1 2016, closing a stake of 3,149 shares — an estimated $142K sold.

Meditor Group first reported a position in RCKT in Q3 2015 and held it in 2 quarters. The position peaked at $480K in Q3 2015. 58 funds tracked by Wall St. Rank hold RCKT as of Q1 2016.

Meditor Group reported no remaining Rocket Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Meditor Group sold 3,149 Rocket Pharmaceuticals shares in Q1 2016, an estimated $142K.
Meditor Group first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 2 quarters.
Meditor Group's Rocket Pharmaceuticals position peaked at $480K in Q3 2015.
58 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2016.

Based on Meditor Group's 13F filing for Q1 2016, filed 18 Apr 2016.